Rx Products (November 2019)

Pharmacy TimesNovember 2019
Volume 85
Issue 11

The November Rx Products feature fedratinib, ixekizumab, and more.


Manufactured by: Celgene

Indication: The FDA has given Celgene its blessing for fedratinib (Inrebic), indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, including patients previously treated with ruxolitinib (Jakafi). Myelofibrosis is a rare form of bone marrow cancer that disrupts the body’s normal production of blood cells. Inrebic is the first new treatment approved for the disease in nearly a decade.

For more information: celgene.com

IXEKIZUMAB (TALTZ)Manufactured by: Eli Lilly

Indication: Eli Lilly has received a new indication for its Taltz injection 80 mg/mL, now approved for the treatment of adults with active ankylosing spondylitis (AS), also known as Bechterew’s disease. AS is inflammatory arthritis that can cause severe back pain and impact mobility. This is the third indication for the drug, which was first approved in 2016 for the treatment of moderate to severe plaque psoriasis in adults. Its other indication is for the treatment of adults with active psoriatic arthritis. Ixekizumab acts by blocking interleukin 17A, reducing inflammation.

For more information: taltz.com

BAQSIMI (GLUCAGON)Manufactured by: Eli Lilly and Co

Indication: The FDA approved Eli Lilly and Co’s Baqsimi on July 24, and it is expected to be available in pharmacies soon. Baqsimi is a nasally administered antihypoglycemic agent to treat severe hypoglycemia in patients with diabetes 4 years and older. The nasal powder 3-mg dose is the first and only nasally administered glucagon and is compact, portable, and ready to use. It is a single-dose container and cannot be reused.

For more information: lilly.com

UPADACITINIB (RINVOQ)Manufactured by: AbbVie

Indication: The FDA has approved AbbVie’s Rinvoq, a 15-mg, once- daily oral Janus kinase inhibitor. It is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate. The drug was evaluated across multiple clinical studies in more than 2600 people and was shown to significantly help relieve RA symptoms in the majority of people, including joint pain, stiffness, and swelling. It is also confirmed to help stop further joint damage. The medication comes in an easy-to-open bottle with an easy-grip texture, embedded tool to puncture the foil liner, and a wide profile.

For more information: rinvoq.com

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.